Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial

In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors. Health-related quality of life (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Réa, Delphine, Boquimpani, Carla, Mauro, Michael J., Minami, Yosuke, Allepuz, Alex, Maheshwari, Vikalp Kumar, D’Alessio, Denise, Wu, Ying, Lawrance, Rachael, Narbutas, Sarunas, Sharf, Giora, Hochhaus, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169655/
https://www.ncbi.nlm.nih.gov/pubmed/37069326
http://dx.doi.org/10.1038/s41375-023-01888-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169655/
https://www.ncbi.nlm.nih.gov/pubmed/37069326
http://dx.doi.org/10.1038/s41375-023-01888-y

Ejemplares similares